PGⅠ、CA19-9及CEA水平对胃癌诊断与预后评估的价值  

Value of PG Ⅰ,CA19-9 and CEA levels for diagnosing gastric cancer and evaluating its prognosis

作　　者：吴钢[1] 赵昌杰[1] 陈林[1] 姜琦 苏丽萍[1] 

机构地区：[1]南通大学附属东台医院消化内科,南通224200 [2]上海消化外科研究所,上海胃肿瘤重点实验室

出　　处：《山西医科大学学报》2016年第11期1001-1004,共4页Journal of Shanxi Medical University

基　　金：国家自然科学基金资助项目(30900670)

摘　　要：目的探讨血清胃蛋白酶原Ⅰ（PGⅠ）、糖类抗原19-9（CA19-9）及癌胚抗原（CEA）在胃癌诊断和预后评估的价值。方法选取2013-01～2015-05在我院治疗的胃癌患者52例,胃炎患者47例和其他肿瘤患者50例,同时选取51例健康受试者作为对照组。采用放射免疫分析法检测各组受试者血清PGⅠ、CA19-9及CEA水平。结果胃癌组PGⅠ为（40.22±12.54）μg/L,明显低于其他组（P〈0.05）;胃癌组CA19-9为（87.30±34.21）U/ml,明显高于其他组（P〈0.05）;胃癌组CEA为（77.52±32.10）μg/L,高于胃炎组和对照组,而低于其他肿瘤组（P〈0.05）;PGⅠ、CA19-9及CEA诊断胃癌的灵敏度为69.23%,76.92%和57.69%,特异度为91.84%,96.94%和88.78%,三者联合检测的灵敏度和特异度分别为86.54%和96.94%;胃癌复发患者PGⅠ为（51.04±11.82）μg/L,明显低于无复发患者（P〈0.05）,而CA19-9及CEA为（47.83±9.81）U/ml和（11.73±2.49）μg/L,明显高于无复发患者（P〈0.05）。结论 PGⅠ、CA19-9及CEA水平在胃癌诊断和预后评估有较高的应用价值。Objective To investigate the value of serum pepsinogenⅠ（ PGⅠ）,carbohydrate antigen 19-9（ CA19-9） and carcinoembryonic antigen（ CEA） in diagnosis of gastric cancer and evaluation of prognosis. Methods From January 2013 to May 2015,the clinical data of52 cases of gastric cancer,47 cases of gastritis and 50 cases of other tumors were collected,and 51 healthy subjects were chosen as control group. The radioimmunoassay was used to detect the levels of serum PGⅠ,CA19-9 and CEA in each group. Results PGⅠwas（ 40. 22 ±12. 54） μg / L in gastric cancer group,significantly lower than in the other groups（ P〈0. 05）. CA19-9 was（ 87. 30 ± 34. 21） U / ml in gastric cancer group,which was significantly higher than in the other groups（ P〈0. 05）. CEA was（ 77. 52 ± 32. 10） μg / L in gastric cancer group,which was higher than that in gastritis group and control group,but lower than in the other tumor group（ P〈0. 05）. The sensitivity of PG Ⅰ,CA19-9 and CEA in the diagnosis of gastric cancer was 69. 23%,76. 92% and 57. 69%,respectively,and the specificity was 91. 84%,96. 94% and 88. 78%. The sensitivity and specificity of the combined detection were 86. 54% and 96. 94%. PGⅠ in patients with gastric cancer recurrence was（ 51. 04 ± 11. 82） μg / L,significantly lower than that of patients without gastric cancer recurrence（ P〈0. 05）. Serum levels of CA19-9 and CEA were（ 47. 83 ± 9. 81） U / ml and（ 11. 73 ± 2. 49） μg / L in patients with gastric cancer recurrence,significantly higher than that of patients without gastric cancer recurrence（ P〈0. 05）. Conclusion PG Ⅰ,CA19-9 and CEA levels have higher application value in the diagnosis and prognosis evaluation of gastric cancer.

关 键 词：胃癌 癌胚抗原 糖类抗原19-9 胃蛋白酶原Ⅰ 预后 诊断 

分 类 号：R735.2[医药卫生—肿瘤]